Press Releases April 15, 2026 04:25 PM

Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the First Quarter Ended March 31, 2026

Carlyle Secured Lending, Inc. to announce Q1 2026 earnings and host earnings call on May 11, 2026

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
CGBD

Carlyle Secured Lending, Inc. (NASDAQ: CGBD), a business development company focusing on senior secured lending to U.S. middle-market companies, announced its Q1 2026 earnings release and conference call scheduled for May 11, 2026. The call will discuss the financial results for the quarter ended March 31, 2026, with access available via webcast.

Carlyle Secured Lending, Inc. Schedules Earnings Release and Quarterly Earnings Call to Discuss its Financial Results for the First Quarter Ended March 31, 2026
CGBD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Carlyle Secured Lending is a NASDAQ-listed business development company focusing on senior secured loans to U.S. middle-market companies.
  • The company will report Q1 2026 earnings and host a conference call on May 11, 2026.
  • Carlyle Secured Lending is externally managed by Carlyle Global Credit Investment Management, a subsidiary of global investment firm Carlyle Group (NASDAQ: CG).

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Carlyle Secured Lending, Inc. (“Carlyle Secured Lending”) (NASDAQ: CGBD) will host a conference call at 12:00 p.m. (Eastern Time) on Monday, May 11, 2026 to announce its financial results for the first quarter ended March 31, 2026. The Company will report its quarterly financial results on Monday, May 11, 2026.

The conference call will be available via public webcast via a link on Carlyle Secured Lending’s website at carlylesecuredlending.com and will also be available on the website soon after the call’s completion.

About Carlyle Secured Lending, Inc.

Carlyle Secured Lending, Inc. is a publicly traded (NASDAQ: CGBD) business development company (“BDC”) which began investing in 2013. The Company focuses on providing directly originated, financing solutions across the capital structure, with a focus on senior secured lending to middle-market companies primarily located in the United States. Carlyle Secured Lending is externally managed by Carlyle Global Credit Investment Management L.L.C., an SEC-registered investment adviser and wholly owned subsidiary of Carlyle.

Web: carlylesecuredlending.com

About Carlyle

Carlyle (“Carlyle,” or the “Adviser”) (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Carlyle AlpInvest. With $477 billion of assets under management as of December 31, 2025, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. Carlyle employs more than 2,500 people in 27 offices across four continents. Further information is available at www.carlyle.com. Follow Carlyle on X @OneCarlyle and LinkedIn at The Carlyle Group.

Contacts:

Investors:Media:Nishil MehtaKristen Ashton+1-212-813-4918+1-212-813-4763publicinvestor@[email protected]

Risks

  • Earnings results may reflect credit risk and performance of middle-market lending in the U.S. economy impacting BDCs and credit markets.
  • Market volatility or adverse economic conditions could affect Carlyle Secured Lending’s financial performance.
  • Dependence on Carlyle Global Credit Investment Management for external management adds operational risk if adviser faces challenges.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026